PepEvolutionGonadorelin
Factrel
Synthetic GnRH approved as a diagnostic — now a widely-compounded, physiologic alternative to hCG for TRT support.
Verdict — B · Viable
A well-tolerated, physiologic GnRH that has become a mainstream TRT-support option through compounding pharmacies — FDA precedent as a diagnostic and a benign safety profile. Held to a B by thin off-label outcome data, a demanding short half-life, and unverified gray-market sourcing. A reasonable hCG alternative obtained from a licensed compounder.
Overview
Gonadorelin is synthetic gonadotropin-releasing hormone, FDA-approved (Factrel) as a diagnostic agent for pituitary function. Because it stimulates the body's own LH/FSH release, it is now widely compounded and used off-label as a short-acting, physiologic alternative to hCG for maintaining testicular function during testosterone therapy. Its very short half-life makes it well-tolerated but demands frequent dosing, and the off-label TRT-support evidence is thinner than its long-standing diagnostic record.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.